$804 Million is the total value of Invesco Private Capital's 9 reported holdings in Q1 2015. The portfolio turnover from Q4 2014 to Q1 2015 was 44.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NVGS | Navigator Holdings Ltd. | $417,600,000 | -9.3% | 21,863,874 | 0.0% | 51.94% | -2.4% | |
| TLMR | Talmer Bancorp Inc | $148,013,000 | +9.1% | 9,664,579 | 0.0% | 18.41% | +17.4% | |
| XCO | Exco Resources Inc. | $93,520,000 | -15.7% | 51,104,050 | 0.0% | 11.63% | -9.2% | |
| SNBC | Sun Bancorp Inc. | $80,478,000 | -2.5% | 4,255,848 | 0.0% | 10.01% | +4.9% | |
| CACB | Cascade Bancorp | $55,050,000 | -7.5% | 11,468,750 | 0.0% | 6.85% | -0.4% | |
| XENE | Xenon Pharmaceutical, Inc. Common Stock | $7,626,000 | -13.2% | 444,655 | 0.0% | 0.95% | -6.5% | |
| IPHI | Sell | Inphi Corporation Common Stock | $1,095,000 | -17.0% | 61,424 | -14.0% | 0.14% | -10.5% |
| TTOO | New | T2 Biosystems, Inc. Common Stock | $543,000 | – | 35,000 | +100.0% | 0.07% | – |
| NMBL | New | Nimble Storage, Inc. Common Stocl | $147,000 | – | 6,594 | +100.0% | 0.02% | – |
| CYCC | Exit | Cyclacel Pharmaceuticals | $0 | – | -58,158 | -100.0% | -0.01% | – |
| 2978PS | Exit | E2Open, Inc. | $0 | – | -671,123 | -100.0% | -0.74% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| NAVIGATOR HOLDINGS LTD. | 24 | Q3 2019 | 99.0% |
| Sun Bancorp Inc. | 19 | Q4 2017 | 35.4% |
| Exco Resources Inc. | 19 | Q4 2017 | 24.9% |
| XENON PHARMACEUTICALS, INC. | 18 | Q1 2019 | 1.0% |
| Cascade Bancorp | 16 | Q1 2017 | 20.3% |
| E2Open, Inc. Common Stock | 7 | Q4 2014 | 3.1% |
| Cyclacel Pharmaceuticals k | 7 | Q4 2014 | 0.1% |
| Talmer Bancorp Inc | 6 | Q2 2015 | 20.5% |
| LipoScience, Inc. Common Stock | 6 | Q3 2014 | 0.5% |
| Harmonic, Inc. Common Stock | 5 | Q2 2014 | 0.4% |
View Invesco Private Capital's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| E2open Inc | February 06, 2015 | 671,123 | 2.3% |
| CALLIDUS SOFTWARE INC | February 14, 2011 | 1,601,406 | 5.0% |
| MONTPELIER RE HOLDINGS LTDSold out | February 14, 2011 | 0 | 0.0% |
| Cyclacel Pharmaceuticals, Inc. | April 07, 2006 | 931,313 | - |
| SIGMATEL INC | February 11, 2005 | 447,881 | 1.3% |
| HEALTH GRADES INCSold out | March 12, 2003 | 0 | 0.0% |
| ALLOS THERAPEUTICS INC | October 02, 2002 | 861,961 | 3.8% |
| HEALTHGRADES COM INCSold out | March 23, 2001 | 0 | 0.0% |
| REPEATER TECHNOLOGIES INC | February 27, 2001 | 2,164,656 | 9.3% |
| TRANSGENOMIC INC | February 27, 2001 | 2,292,426 | 10.7% |
View Invesco Private Capital's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2019-12-05 |
| 4 | 2019-11-27 |
| 13F-HR | 2019-11-14 |
| 13F-HR | 2019-08-14 |
| 13F-HR | 2019-05-15 |
| 3 | 2019-04-08 |
| 13F-HR | 2019-02-14 |
| 13F-HR | 2018-11-14 |
| 13F-HR | 2018-08-14 |
| 13F-HR | 2018-05-15 |
View Invesco Private Capital's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.